Sensible Biotechnologies announced a partnership to develop an in vivo microbial mRNA manufacturing platform with Ginkgo Bioworks, which is building the leading platform for cell programming and biosecurity. Through this partnership, Sensible and Ginkgo aim to develop an in vivo alternative to conventional in vitro mRNA production technology.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on DNA:
- Silicon Valley Bank – The Aftermath. Which Companies Were Impacted?
- Gingko says roughly 6% of cash, cash equivalents held in SVB accounts
- Ginkgo Bioworks price target lowered to $3 from $4 at BTIG
- Ginkgo Bioworks sees 2023 revenue at least $275M, consensus $381.51M
- Ginkgo Bioworks reports Q4 EPS (10c), consensus (21c)